Company: NDRA
Filing Date: 2025-07-16
Form Type: S-1/A
Source: 0001654954-25-008117
Chunk: 4

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-07-16
Form: S-1/A
Chunk 4
---
 presented in this table does not give effect to any exercise of the Underwriter Warrants or Pre-Funded Warrants.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

We have granted the Underwriter a 45-day option to purchase from us additional 2,355,000 shares of common stock at $ per share, less the underwriting discount and commissions, to cover overallotments, if any. If the Underwriter exercises this option in full, the total underwriting discounts and commissions payable will be approximately $ and the total proceeds to us, before expenses, will be approximately $ .

Investing in our securities involves a high degree of risk. See “Risk Factors” on page 15 of this prospectus and elsewhere in any supplements for a discussion of information that should be considered in connection with an investment in our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

Delivery of the securities offered hereby is expected to be made on or about , 2025, subject to satisfaction of certain customary closing conditions.

<div align='center'>The date of this prospectus is , 2025.

Sole Bookrunner

Lucid Capital Markets</div>

<div align='center'>TABLE OF CONTENTS</div>

|                                                      |     | Page |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS |     |    2 |
| PROSPECTUS SUMMARY                                   |     |    4 |
| RISK FACTORS                                         |     |   15 |
| USE OF PROCEEDS                                      |     |   27 |
| CAPITALIZATION                                       |     |   28 |
| DILUTION                                             |     |   29 |
| DESCRIPTION OF OUR SECURITIES                        |     |   30 |
| UNDERWRITING                                         |     |   35 |
| LEGAL MATTERS                                        |     |   37 |
| EXPERTS                                              |     |   37 |
| WHERE YOU CAN FIND MORE INFORMATION                  |     |   37 |
| INCORPORATION BY REFERENCE                           |     |   38 |

You should rely only on the information contained in this prospectus. Neither we nor the Underwriter has authorized anyone to provide you with different information and, if provided, such information or representations must not be relied upon as having been authorized by us or the Underwriter. This prospectus shall not constitute an offer to sell